By Denny Jacob A 60 Degrees Pharmaceuticals subsidiary won’t resubmit its investigational new drug application for ACLR8-LR, a Phase IIB study of tafenoquine…
Markets – MarketWatch
60 Degrees Pharmaceuticals Subsidiary Won’t Resubmit ACLR8-LR Application for Covid-19 Markets – MarketWatch
